UCB
A biopharmaceutical company focused on severe diseases in neurology and immunology.
UCB | BR
Overview
Corporate Details
- ISIN(s):
- BE0002730118 (+5 more)
- LEI:
- 2138008J191VLSGY5A09
- Country:
- Belgium
- Address:
- ALLÉE DE LA RECHERCHE 60, 1070 ANDERLECHT
- Website:
- https://www.ucb.com/
- Sector:
- Manufacturing
Description
UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2025-03-21 07:00 |
2.1 Proxy General Meeting 24 April 2025 - ENG - Final.pdf
|
English | PDF • 1.1 MB | ||
| 2025-03-21 07:00 |
7.2. FR_Remuneration Report 2024 FR.pdf
|
French | PDF • 390.1 KB | ||
| 2025-03-21 07:00 |
5.3. UCB_ IAR _2024_NL.pdf
|
Dutch | PDF • 14.2 MB | ||
| 2025-03-21 07:00 |
3.1. UCB SA_Management Report Statutory Accounts 2024 EN Final.pdf
|
English | PDF • 1.1 MB | ||
| 2025-03-21 07:00 |
6.2. Statutory Account NBB_UCB SA_31.12.2024 _FR Final.pdf
|
French | PDF • 375.8 KB | ||
| 2025-03-21 07:00 |
2.3. Proxy General Meeting 24 April 2025 - NL - Final.pdf
|
Dutch | PDF • 1.1 MB | ||
| 2025-03-21 07:00 |
4.1. UCB_SA_Statutory Auditor Report 2024 EN.pdf
|
English | PDF • 166.4 KB | ||
| 2025-03-21 07:00 |
9.2. Explanatory Note on Remuneration_FR.pdf
|
French | PDF • 321.4 KB | ||
| 2025-03-21 07:00 |
3.3. UCB SA_Management Report Staturoy Accounts 2024 NL Final.pdf
|
Dutch | PDF • 1.1 MB | ||
| 2025-03-21 07:00 |
5.1 UCB_IAR_2024_ENG.pdf
|
English | PDF • 15.5 MB | ||
| 2025-03-21 07:00 |
8.2. Remuneration_Policy_2025_FR.pdf
|
French | PDF • 620.4 KB | ||
| 2025-03-21 07:00 |
4.3. UCB_SA_Statutory Auditor Report 2024 NL.pdf
|
Dutch | PDF • 353.2 KB | ||
| 2025-03-21 07:00 |
9.1 Explanatory Note on Remuneration_EN.pdf
|
English | PDF • 244.2 KB | ||
| 2025-03-21 07:00 |
7.1. ENG_Remuneration Report 2024.pdf
|
English | PDF • 197.0 KB | ||
| 2025-03-21 07:00 |
3.1. UCB SA_Management Report Statutory Accounts 2024 EN Final.pdf
|
English | PDF • 1.1 MB |
Automate Your Workflow. Get a real-time feed of all UCB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for UCB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for UCB via our API.
Peer Companies
